Sgd Pharma, headquartered in France, is a prominent player in the rubber and plastic products industry, specifically within the pharmaceutical packaging sector. Established in 1996, the company has made significant strides in providing innovative solutions for the global market, with major operational regions across Europe, Asia, and the Americas.
Specialising in the design and manufacture of high-quality glass and plastic containers, Sgd Pharma stands out for its commitment to sustainability and advanced technology. Their core offerings include vials, bottles, and closures that meet stringent regulatory standards, ensuring product safety and integrity. With a strong market position, Sgd Pharma has achieved notable milestones, including numerous certifications and awards for excellence in quality and environmental responsibility.
+29 vs industry average
Sgd Pharma’s score of 51 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Sgd Pharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Rubber and Plastic Products is among the most carbon-intensive industries
Industry performance
The Rubber and Plastic Products industry has reduced its overall emissions by 30% since 2018
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Sgd Pharma's reported carbon emissions
SGD Pharma, operating in the rubber and plastic products industry in France, has published comprehensive carbon emissions data and climate commitments.
Carbon Emissions:
For the reporting year 2025, SGD Pharma reported a total of approximately 477.5 million kg CO2e. This figure comprises:
- Scope 1 emissions: approximately 125.0 million kg CO2e
- Scope 2 emissions (market-based): approximately 33.8 million kg CO2e
- Scope 3 emissions: approximately 318.8 million kg CO2e
The previous year, 2024, saw total emissions of approximately 501.4 million kg CO2e, broken down as:
- Scope 1 emissions: approximately 121.6 million kg CO2e
- Scope 2 emissions (market-based): approximately 59.9 million kg CO2e
- Scope 3 emissions: approximately 328.9 million kg CO2e
In 2023, total emissions were approximately 510.0 million kg CO2e, with:
- Scope 1 emissions: approximately 138.1 million kg CO2e
- Scope 2 emissions (market-based): approximately 61.6 million kg CO2e
- Scope 3 emissions: approximately 320.3 million kg CO2e
For 2022, total emissions were approximately 488.2 million kg CO2e, including:
- Scope 1 emissions: approximately 142.4 million kg CO2e
- Scope 2 emissions (market-based): approximately 76.3 million kg CO2e
- Scope 3 emissions: approximately 319.5 million kg CO2e
In 2021, reported Scope 1 and Scope 2 emissions totalled approximately 198.7 million kg CO2e, with Scope 1 emissions around 131.1 million kg CO2e and Scope 2 emissions (market-based) at approximately 67.6 million kg CO2e. Scope 3 data was not disclosed for this year.
Earlier data includes:
- 2020: Scope 1 and 2 market-based emissions were approximately 209.7 million kg CO2e.
- 2019: Scope 1 and 2 market-based emissions were approximately 200.4 million kg CO2e.
- 2018: Scope 1 and 2 emissions totalled approximately 191.6 million kg CO2e.
Climate Commitments:
SGD Pharma has established several reduction targets:
- A long-term commitment to achieve carbon neutrality by 2050.
- A near-term target to reduce Scope 1 and 2 CO2 emissions by 42% by 2030, compared to 2022 levels, aligning with the 1.5°C climate threshold.
- SGD Pharma's plants in France, Germany, India, and China aim to cut Scope 1 and 2 emissions by 35% by 2030 and by 65% by 2040, using a 2020 baseline.
- Additionally, a long-term goal is set to achieve a 65% reduction in CO2 emissions by 2040, with a commitment to continue efforts to increase this target.
The company has not publicly committed to Science Based Targets initiative (SBTi) targets at this time.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Sgd Pharma’s Climate Goals (2030 & 2050)
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Sgd Pharma
Frequently asked questions
Common questions about Sgd Pharma’s sustainability data and climate commitments
Data year: 2025
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project